Breaking the barriers for the delivery of amikacin: Challenges, strategies, and opportunities

Maxwell, Amala; Ghate, Vivek; Aranjani, Jesil Mathew; Lewis, Shaila

doi:10.1016/j.lfs.2021.119883

Cited by 20 publications

(8 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aminoglycoside antibiotics also have broad-spectrum bactericidal activity. However, AMI is known to develop resistance very slowly due to its complex structure ( 25 ). In the surveillance program, the susceptible rate of COL to MDR-PA can achieve 98.9% ( n = 12,972), and the susceptible rate of LEV and AMI to MDR-PA is 62.3% and 64.1%, respectively ( 9 , 10 ).…”

Section: Discussionmentioning

confidence: 99%

The Efficacy of Colistin Combined with Amikacin or Levofloxacin against Pseudomonas aeruginosa Biofilm Infection

Wang

et al. 2022

Microbiol Spectr

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

The Efficacy of Colistin Combined with Amikacin or Levofloxacin against Pseudomonas aeruginosa Biofilm Infection

Wang

et al. 2022

Microbiol Spectr

View full text Add to dashboard Cite

show abstract

“…Additionally, if the above-mentioned strategy is still insufficient for the desired results, it is also worth mentioning that surfactants such as Poloxamine 908 are able to influence the uptake in desired tissues (decreasing the liver uptake while increasing the spleen uptake) [ 140 ]. Some polymeric nanoparticles are also able to increase uptake in a specific tissue, further helping to target the desired infection location (such as Amikacin-bearing PLGA nanoparticles that have an increased uptake in Peyer’s patches compared to plain Amikacin) [ 141 ].…”

Section: Nanotechnology Used As a Diagnostic Methods And In Antimicro...mentioning

confidence: 99%

Nanotechnology Involved in Treating Urinary Tract Infections: An Overview

et al. 2023

View full text Add to dashboard Cite

Considered as the most frequent contaminations that do not require hospitalization, urinary tract infections (UTIs) are largely known to cause significant personal burdens on patients. Although UTIs overall are highly preventable health issues, the recourse to antibiotics as drug treatments for these infections is a worryingly spread approach that should be addressed and gradually overcome in a contemporary, modernized healthcare system. With a virtually alarming global rise of antibiotic resistance overall, nanotechnologies may prove to be the much-needed ‘lifebuoy’ that will eventually suppress this prejudicial phenomenon. This review aims to present the most promising, currently known nano-solutions, with glimpses on clinical and epidemiological aspects of the UTIs, prospective diagnostic instruments, and non-antibiotic treatments, all of these engulfed in a comprehensive overview.

show abstract

“…In detail, amikacin, a polycationic aminoglycoside, is encapsuled by liposomes composed of dipalmitoyl phosphatidyl choline (DPPC) and cholesterol to form the neutral NPs, which not only protect amikacin from attraction of negatively charged EPS matrix, but also have an efficiently penetrating biofilms and a highly effective bactericidal effect. [118,119] Many clinical practices have also proved that Arikayce can really promote the penetration of amikacin into non-tuberculosis mycobacterium biofilms, [20] and efficiently treat complex Mycobacterium avium lung disease that is difficult to treat with conventional therapies. [120] The design and construction of Arikayce represents an excellent strategy.…”

Section: Charge On the Particle Surfacementioning

confidence: 99%

Strategies to Promote the Journey of Nanoparticles Against Biofilm‐Associated Infections

Wang,

et al. 2024

Small

View full text Add to dashboard Cite

Biofilm‐associated infections are one of the most challenging healthcare threats for humans, accounting for 80% of bacterial infections, leading to persistent and chronic infections. The conventional antibiotics still face their dilemma of poor therapeutic effects due to the high tolerance and resistance led by bacterial biofilm barriers. Nanotechnology‐based antimicrobials, nanoparticles (NPs), are paid attention extensively and considered as promising alternative. This review focuses on the whole journey of NPs against biofilm‐associated infections, and to clarify it clearly, the journey is divided into four processes in sequence as 1) Targeting biofilms, 2) Penetrating biofilm barrier, 3) Attaching to bacterial cells, and 4) Translocating through bacterial cell envelope. Through outlining the compositions and properties of biofilms and bacteria cells, recent advances and present the strategies of each process are comprehensively discussed to combat biofilm‐associated infections, as well as the combined strategies against these infections with drug resistance, aiming to guide the rational design and facilitate wide application of NPs in biofilm‐associated infections.

show abstract

Breaking the barriers for the delivery of amikacin: Challenges, strategies, and opportunities

Cited by 20 publications

References 96 publications

The Efficacy of Colistin Combined with Amikacin or Levofloxacin against Pseudomonas aeruginosa Biofilm Infection

The Efficacy of Colistin Combined with Amikacin or Levofloxacin against Pseudomonas aeruginosa Biofilm Infection

Nanotechnology Involved in Treating Urinary Tract Infections: An Overview

Strategies to Promote the Journey of Nanoparticles Against Biofilm‐Associated Infections

Contact Info

Product

Resources

About